Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5 Billion KRW | 133.34% |
| 2022 | -15 Billion KRW | -0.16% |
| 2021 | -14.98 Billion KRW | -316.68% |
| 2020 | 6.91 Billion KRW | 165.34% |
| 2019 | -10.58 Billion KRW | -660.32% |
| 2018 | 1.88 Billion KRW | 76.94% |
| 2017 | 1.06 Billion KRW | -86.47% |
| 2016 | 7.89 Billion KRW | -19.17% |
| 2015 | 9.76 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -26.51 Billion KRW | -821.27% |
| 2024 Q1 | -2.87 Billion KRW | -28.64% |
| 2023 FY | 5 Billion KRW | 133.34% |
| 2023 Q3 | -4.11 Billion KRW | -204.64% |
| 2023 Q2 | -1.34 Billion KRW | -110.62% |
| 2023 Q1 | 12.7 Billion KRW | 402.49% |
| 2023 Q4 | -2.23 Billion KRW | 45.58% |
| 2022 Q4 | -4.19 Billion KRW | 4.33% |
| 2022 Q1 | -4.44 Billion KRW | 59.82% |
| 2022 Q2 | -1.97 Billion KRW | 55.64% |
| 2022 FY | -15 Billion KRW | -0.16% |
| 2022 Q3 | -4.38 Billion KRW | -122.45% |
| 2021 Q4 | -11.06 Billion KRW | -3016.8% |
| 2021 Q2 | 267.39 Million KRW | 120.32% |
| 2021 Q1 | -1.31 Billion KRW | -577.74% |
| 2021 FY | -14.98 Billion KRW | -316.68% |
| 2021 Q3 | -355.16 Million KRW | -232.82% |
| 2020 Q3 | 429.92 Million KRW | -82.02% |
| 2020 Q1 | 3.81 Billion KRW | 127.15% |
| 2020 FY | 6.91 Billion KRW | 165.34% |
| 2020 Q4 | 275.38 Million KRW | -35.95% |
| 2020 Q2 | 2.39 Billion KRW | -37.38% |
| 2019 FY | -10.58 Billion KRW | -660.32% |
| 2019 Q3 | 1.1 Billion KRW | -42.8% |
| 2019 Q2 | 1.93 Billion KRW | 459.83% |
| 2019 Q1 | 344.74 Million KRW | -58.22% |
| 2019 Q4 | -14.06 Billion KRW | -1374.49% |
| 2018 Q1 | 343.62 Million KRW | -4.67% |
| 2018 FY | 1.88 Billion KRW | 76.94% |
| 2018 Q4 | 825.2 Million KRW | 54.78% |
| 2018 Q3 | 533.16 Million KRW | 185.05% |
| 2018 Q2 | 187.04 Million KRW | -45.57% |
| 2017 Q2 | 215.57 Million KRW | 0.0% |
| 2017 Q4 | 360.45 Million KRW | -26.67% |
| 2017 FY | 1.06 Billion KRW | -86.47% |
| 2017 Q3 | 491.56 Million KRW | 128.03% |
| 2016 FY | 7.89 Billion KRW | -19.17% |
| 2015 FY | 9.76 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 169.695% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 91.37% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 108.399% |
| HANDOK Inc. | -28.79 Billion KRW | 117.379% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 159.473% |
| Yuhan Corporation | 93.5 Billion KRW | 94.648% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 55.003% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 120.171% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 96.578% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -42.642% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 299.677% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 341.319% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 210.606% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 77.59% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 169.695% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 123.899% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -39.666% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 104.232% |
| JW Holdings Corporation | 19.02 Billion KRW | 73.696% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 106.341% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 97.645% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 86.476% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 108.73% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 18.247% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -200.849% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 169.695% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 86.461% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 95.512% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 86.476% |
| Yuhan Corporation | 93.5 Billion KRW | 94.648% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 130.799% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 229.137% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 18.213% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 86.476% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 73.528% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 89.63% |
| CKD Bio Corp. | -24.19 Billion KRW | 120.687% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 79.074% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 81.76% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 83.191% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 108.73% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 89.353% |
| Boryung Corporation | 40.2 Billion KRW | 87.551% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 115.974% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 299.677% |
| JW Lifescience Corporation | 28.14 Billion KRW | 82.217% |